GE
Genmab A/S
GE9.F · FSX
278.20 € +0.91% (+2.50 €)
1M +2.66%
Market Cap $21.0B
P/E Ratio 26.85x
Div. Yield -
ROE 13.48%
Bulios Fair Price
372.81 €
34.0% upside
Current Price
278.2 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GE9.F is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
43 /100
Fair P/E 26.85x
EV/EBITDA 18.10x
P/S 5.12x
Growth
0 /100
Declining EPS growth 42.26%
Rev. growth 35.73%
FCF growth 30.83%
Profitability
100 /100
Strong Gross margin 93.03%
Net margin 19.07%
Op. margin 32.30%
Quality
53 /100
Average ROIC 9.86%
ROE 13.48%
ROA 6.26%
Debt
60 /100
Moderate Debt/Equity 0.89x
Current ratio 2.46x
Int. coverage 5.09x
Stability
40 /100
Moderate Beta 0.69x
Rev. volatility 60.78%
EPS volatility 86.03%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GE9.F
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
3,029
Headquarters
Copenhagen
Upcoming events
05 NOV
Earnings
Upcoming earnings report